Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 67 citing articles:

Merits and boundaries of the BCLC staging and treatment algorithm: Learning from the past to improve the future with a novel proposal
Franco Trevisani, Alessandro Vitale, Masatoshi Kudo, et al.
Journal of Hepatology (2024) Vol. 80, Iss. 4, pp. 661-669
Closed Access | Times Cited: 25
EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma
Bruno Sangro, Lorenza Rimassa, Maxime Ronot, et al.
Journal of Hepatology (2024)
Closed Access | Times Cited: 17
Conversion therapy for advanced hepatocellular carcinoma in the era of precision medicine: Current status, challenges and opportunities
Ming‐Da Wang, Xuejun Xu, Ke‐Chun Wang, et al.
Cancer Science (2024) Vol. 115, Iss. 7, pp. 2159-2169
Open Access | Times Cited: 10
Urgent Global Need for PIVKA-II and AFP-L3 Measurements for Surveillance and Management of Hepatocellular Carcinoma
Masatoshi Kudo
Liver Cancer (2024) Vol. 13, Iss. 2, pp. 113-118
Open Access | Times Cited: 6
Outcomes of Salvage Surgery Versus Non-Salvage Surgery for Initially Unresectable Hepatocellular Carcinoma After Conversion Therapy with Transcatheter Arterial Chemoembolization Combined with Lenvatinib Plus Anti-PD-1 Antibody: A Multicenter Retrospective Study
Jiayi Wu, Jiayi Wu, Yang-Kai Fu, et al.
Annals of Surgical Oncology (2024) Vol. 31, Iss. 5, pp. 3073-3083
Closed Access | Times Cited: 5
Immune Checkpoint Inhibitors plus Anti-VEGF/Tyrosine Kinase Inhibitors Combined with TACE (Triple Therapy) in Unresectable Hepatocellular Carcinoma
Masatoshi Kudo
Liver Cancer (2024) Vol. 13, Iss. 3, pp. 227-234
Open Access | Times Cited: 5
Clinical Outcomes and Histologic Findings of Patients With Hepatocellular Carcinoma With Durable Partial Response or Durable Stable Disease After Receiving Atezolizumab Plus Bevacizumab
Ying‐Chun Shen, Tsung‐Hao Liu, Alan Nicholas, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 34, pp. 4060-4070
Closed Access | Times Cited: 5
Clinical utility of the novel oncological criteria of resectability for advanced hepatocellular carcinoma
Junichi Shindoh, Yusuke Kawamura, Keiichi Akahoshi, et al.
Liver Cancer (2024), pp. 1-9
Open Access | Times Cited: 4
Conversion Therapy Strategy: A Novel GPC3-Targeted Multimodal Organic Phototheranostics Platform for Mid-late-stage Hepatocellular Carcinoma
Fan Wu, Xin Kuang, Shaocong Deng, et al.
Materials Today Bio (2025) Vol. 30, pp. 101442-101442
Open Access
Systemic therapy for hepatocellular carcinoma, from the early to the advanced stage: a Japanese perspective
Masafumi Ikeda, Chigusa Morizane, Makoto Ueno, et al.
Japanese Journal of Clinical Oncology (2025)
Open Access
Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stages
Da-Long Yang, Lin Ye, Fanjian Zeng, et al.
Hepatology (2025)
Closed Access
The benefit of conversion therapy for patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab using newly established oncological resectability criteria in Japan
Shigeo Shimose, Issei Saeki, Takanori Ito, et al.
Hepatology International (2025)
Closed Access
Proposal of discontinuation criteria of atezolizumab plus bevacizumab after curative conversion therapy for unresectable early-to-intermediate-stage hepatocellular carcinoma: a multicenter proof-of-concept study
Tomoko Aoki, Masatoshi Kudo, Naoshi Nishida, et al.
Journal of Gastroenterology (2025)
Open Access
Multi-scale camouflaged feature mining and fusion network for liver tumor segmentation
Lei Yang, Jiawei Zhang, Tao Wang, et al.
Engineering Applications of Artificial Intelligence (2025) Vol. 148, pp. 110398-110398
Closed Access
Protocol of the IMPACT study: randomized, multicenter, phase 3 study evaluating the efficacy of immunotherapy (Atezolizumab) plus anti-VEGF therapy (Bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma
Yoshihisa Kodama, Kazuomi Ueshima, Michihisa Moriguchi, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access
A questionnaire survey to explore the current treatment policies adopted for patients with advanced hepatocellular carcinoma at board‐certified HPB training institutions in Japan: A JSHBPS project study 2023, Part 1
Yuta Kobayashi, Masaru Matsumura, S. Okubo, et al.
Journal of Hepato-Biliary-Pancreatic Sciences (2025)
Closed Access
Prognostic factors and clinical significance of preoperative systemic therapy in patients with borderline resectable hepatocellular carcinoma: A JSHBPS project study 2023, Part 2
Yuta Kobayashi, Masaru Matsumura, Shohei Komatsu, et al.
Journal of Hepato-Biliary-Pancreatic Sciences (2025)
Open Access
Meta-Analysis of Safety and Efficacy of Atezolizumab plus Bevacizumab in Advanced Hepatocelluar Carcinoma
维松 田
Journal of Clinical Personalized Medicine (2025) Vol. 04, Iss. 02, pp. 92-109
Open Access
Improving immunotherapy for the treatment of hepatocellular carcinoma: learning from patients and preclinical models
Romain Désert, Fabio Gianonne, Antonio Saviano, et al.
npj gut and liver. (2025) Vol. 2, Iss. 1
Open Access
Prognostic nutritional index predicts survival in intermediate and advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy combined with PD-(L)1 inhibitors and molecular targeted therapies
Hao-Huan Tang, Mingqing Zhang, Zi-Chen Zhang, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access
Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Japanese perspective
Hironori Koga, Hideki Iwamoto, Hiroyuki Suzuki, et al.
Clinical and Molecular Hepatology (2023) Vol. 29, Iss. 2, pp. 242-251
Open Access | Times Cited: 12
Drug-Off Criteria in Patients with Hepatocellular Carcinoma Who Achieved Clinical Complete Response after Combination Immunotherapy Combined with Locoregional Therapy
Masatoshi Kudo
Liver Cancer (2023) Vol. 12, Iss. 4, pp. 289-296
Open Access | Times Cited: 12
Surveillance, Diagnosis, and Treatment Outcome of Hepatocellular Carcinoma in Japan: 2023 Update
Masatoshi Kudo
Liver Cancer (2023) Vol. 12, Iss. 2, pp. 95-102
Open Access | Times Cited: 11
Advances in Immunotherapy for Hepatocellular Carcinoma
Satoru Hagiwara, Naoshi Nishida, Masatoshi Kudo
Cancers (2023) Vol. 15, Iss. 7, pp. 2070-2070
Open Access | Times Cited: 11
Neoadjuvant therapies in resectable hepatocellular carcinoma: Exploring strategies to improve prognosis
Yanan Ma, Xuemei Jiang, Peipei Song, et al.
BioScience Trends (2024) Vol. 18, Iss. 1, pp. 21-41
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top